catalog number :
MBS2002381
products full name :
Polyclonal Antibody to Epidermal Growth Factor Receptor 2 (EGFR2)
products short name :
[Epidermal Growth Factor Receptor 2 (EGFR2)]
other names :
[receptor tyrosine-protein kinase erbB-2 isoform b; Receptor tyrosine-protein kinase erbB-2; receptor tyrosine-protein kinase erbB-2; erb-b2 receptor tyrosine kinase 2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD_antigen: CD340]
products gene name :
[EGFR2]
other gene names :
[ERBB2; ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; HER2; MLN19; NEU; NGL; MLN 19]
purity :
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
form :
Supplied as solution form in 0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
concentration :
0.67mg/ml
storage stability :
Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 12 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
tested application :
Immunocytochemistry (ICC), Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blot (WB)
app notes :
Western blotting: 0.5-2 ug/mL;1:110-450. Immunohistochemistry: 5-20 ug/mL;1:11-45. Immunocytochemistry: 5-20 ug/mL;1:11-45. Optimal working dilutions must be determined by end user.
image1 heading :
Western Blot (WB)
image2 heading :
Immunohistochemistry (IHC)
other info1 :
Organism Species: Homo sapiens (Human). Source: Polyclonal antibody preparation. Traits: Liquid. Immunogen: Recombinant ErbB2 (Phe376~Gly578) expressed in E.coli
ncbi acc num :
NP_001005862.1
ncbi gb acc num :
NM_001005862.2
ncbi pathways :
Adaptive Immune System Pathway (366160); Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Axon Guidance Pathway (105688); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); Constitutive PI3K/AKT Signaling In Cancer Pathway (685535)
ncbi summary :
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
uniprot summary :
HER2: a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033. Protein type: EC 2.7.10.1; EGFR family; Kinase, protein; Membrane protein, integral; Oncoprotein; Protein kinase, TK; Protein kinase, tyrosine (receptor); TK group. Chromosomal Location of Human Ortholog: 17q12. Cellular Component: apical plasma membrane; basolateral plasma membrane; cytosol; endosome membrane; integral component of membrane; myelin sheath; nucleus; perinuclear region of cytoplasm; plasma membrane; receptor complex. Molecular Function: ATP binding; ErbB-3 class receptor binding; growth factor binding; identical protein binding; phosphatidylinositol-4,5-bisphosphate 3-kinase activity; protein binding; protein C-terminus binding; protein dimerization activity; protein heterodimerization activity; protein phosphatase binding; protein tyrosine kinase activity; Ras guanyl-nucleotide exchange factor activity; signal transducer, downstream of receptor, with protein tyrosine kinase activity; transmembrane receptor activity; transmembrane receptor protein tyrosine kinase activity. Biological Process: cell proliferation; cell surface receptor signaling pathway; cellular response to epidermal growth factor stimulus; cellular response to growth factor stimulus; enzyme linked receptor protein signaling pathway; ERBB2 signaling pathway; heart development; MAPK cascade; motor axon guidance; myelination; negative regulation of ERBB signaling pathway; negative regulation of immature T cell proliferation in the thymus; neuromuscular junction development; oligodendrocyte differentiation; peptidyl-tyrosine phosphorylation; peripheral nervous system development; phosphatidylinositol phosphorylation; phosphoinositide 3-kinase cascade; positive regulation of cell adhesion; positive regulation of cell growth; positive regulation of epithelial cell proliferation; positive regulation of GTPase activity; positive regulation of MAP kinase activity; positive regulation of protein kinase B signaling; positive regulation of protein phosphorylation; positive regulation of protein targeting to membrane; positive regulation of transcription from RNA polymerase I promoter; positive regulation of transcription from RNA polymerase III promoter; positive regulation of translation; protein amino acid phosphorylation; protein autophosphorylation; regulation of angiogenesis; regulation of cell motility; regulation of ERK1 and ERK2 cascade; regulation of microtubule-based process; regulation of transcription from RNA polymerase II promoter; signal transduction; transcription, DNA-dependent; transmembrane receptor protein tyrosine kinase signaling pathway; wound healing. Disease: Gastric Cancer; Glioma Susceptibility 1; Lung Cancer